Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis | SKIN The Journal of Cutaneous Medicine

G Martin

Dr. George Martin Dermatology Associates

B Berman

University of Miami Miller School of Medicine, Miami, Florida and Center for Clinical and Cosmetic Research, Aventura Florida

S Feldman

Wake Forest School of Medicine

A Armstrong

Keck School of Medicine at University of Southern California, Los Angeles, CA, USA

M Edwards

York Health Economics Consortium, York, UK

S Graziadio

York Health Economics Consortium, York, UK

R McCool

York Health Economics Consortium, York, UK

M Arber

York Health Economics Consortium, York, UK

E Carr

York Health Economics Consortium, York, UK

D James

Quantics Biostatistics, Edinburgh, UK

M Chapman-Rounds

Quantics Biostatistics, Edinburgh, UK

E Fumero

Almirall, Barcelona, Spain

M Schuchardt

Almirall, Barcelona, Spain

A Grada

Almirall

Keywords

actinic keratosis, field treatment

Abstract

N/A

References

N/A

Poster PDF

Published

Nov 5, 2021

DOI https://doi.org/10.25251/skin.5.supp.81

How to Cite

Martin, G., Berman, B., Feldman, S., Armstrong , A. ., Edwards, M., Graziadio, S., McCool, R., Arber, M., Carr, E., James, D., Chapman-Rounds, M., Fumero, E., Schuchardt, M., & Grada, A. (2021). Field Treatments for Actinic Keratosis: A Systematic Review and Network Meta-Analysis. SKIN The Journal of Cutaneous Medicine, 5(6), s81. https://doi.org/10.25251/skin.5.supp.81

Issue

Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

Section

Skin Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

Daniel Siegel, Emil Tanghetti, Neil Brody, Michael Freeman, Torsten Skov, Astrid Petersen, Fabrice Clonier, Lynda Spelman, Ingenol Mebutate 0.06% Gel for Field Treatment of Actinic Keratosis on 250 cm2 of Skin on Trunk and Extremities: A Randomized Dose-Finding Trial , SKIN The Journal of Cutaneous Medicine: Vol. 1 No. 3 (2017)
Justin Marson, James Del Rosso, Neal Bhatia, Darrell Rigel, Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 2 (2021)
Melody Maarouf, Bryan Kromenacker, Eric Brucks, Vivian Shi, Expedited Resolution of 5-Fluorouracil-Induced Erythema and Barrier Dysfunction with White Petrolatum , SKIN The Journal of Cutaneous Medicine: Vol. 3 No. 4 (2019)
Danny Zakria, April Armstrong, Brian Berman, James Del Rosso, Mark Lebwohl, Todd Schlesinger, Darrell Rigel, The Importance of Medication Adherence in the Treatment of Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
C William Hanke, Lorne Albrecht, Laerke K Kyhl, Thomas Larrson, Marie L Oesterdal, Lynda Spelman, Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp, or Approximately 250 cm2 on the Chest: A Phase III, Randomized, Controlled Trial , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Chelsea Shope, Tyler Beck, Laura Andrews, Peter Friedman, Lara Wine Lee, Nonthermal Atmospheric Pressure Plasma Technology in Dermatology , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 5 (2022)
Neal Bhatia, Andrew Blauvelt, Edward Lain, Abel Jarell, Janet DuBois, Maria Luisa Tamarit, Meritxell Falqués, Vera Kiyasova, Laura Padullés, Raquel Otero, Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
E Guttman-Yassky, A Blauvelt, L Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson, Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
C Leonardi, K Fahrbach, B Neupane, A Armstrong , K Gordon, S Kiri, V Taieb, L McClung, Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
E Guttman-Yassky, A Blauvelt, L.F. Eichenfield, A Paller, A Armstrong, J Drew, R Gopalan, E Simpson, Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
L Green, A Armstrong, CF Teller, S Bell, T Lin, Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
A Blauvelt, A Armstrong, P Rich, R Kisa, A Guana, X Meng, K Callis Duffin, Secukinumab Provides Complete or Almost-Complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
V Laquer, S Bruce, T Schlesinger, N Zeitouni, A Torres, J Cohen, J Tu, W Hanke, M Goldman, D Ozog, O Markowitz, M Gold, M Nestor, B Berman, G Munavalli, D Pariser, A randomized, double blind, vehicle-controlled multicenter phase III study to evaluate the safety and efficacy of BF-200 ALA and narrowband red light in the treatment of superficial basal cell carcinoma (sBCC) with photodynamic therapy (PDT) , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
D Thaçi, A Armstrong, M Lebwohl, A Blauvelt, C Paul, L Puig, M Wang, V Vanvoorden, C Madden, S Wiegratz, D Deherder, KB Gordon, Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

1 2 > >>